Inclusion Criteria:  Must provide written, signed informed consent for this study. Must have been enrolled in a previous clinical study of RGX-314 in the treatment of nAMD and must have received an SCS injection of RGX-314 in that study. Must be willing and able to comply with all study procedures.  Exclusion Criteria:  1. None